General Biologicals Corporation
General Biologicals Corporation engages in the research, development, manufacture, and sales of in-vitro diagnostics in Taiwan and internationally. It offers ELISA and chemiluminescence immunoassay, molecular and cell diagnostic, and point of care testing services. The company also provides COVID-19, digital pathology, and contract development manufacturing organization solutions; blood screening… Read more
General Biologicals Corporation (4117) - Total Assets
Latest total assets as of June 2025: NT$3.54 Billion TWD
Based on the latest financial reports, General Biologicals Corporation (4117) holds total assets worth NT$3.54 Billion TWD as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
General Biologicals Corporation - Total Assets Trend (2019–2024)
This chart illustrates how General Biologicals Corporation’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
General Biologicals Corporation - Asset Composition Analysis
Current Asset Composition (December 2024)
General Biologicals Corporation's total assets of NT$3.54 Billion consist of 13.1% current assets and 86.9% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 7.4% |
| Accounts Receivable | NT$97.78 Million | 2.9% |
| Inventory | NT$57.08 Million | 1.7% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$32.71 Million | 1.0% |
| Goodwill | NT$21.61 Million | 0.6% |
Asset Composition Trend (2019–2024)
This chart illustrates how General Biologicals Corporation's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: General Biologicals Corporation's current assets represent 13.1% of total assets in 2024, an increase from 11.2% in 2019.
- Cash Position: Cash and equivalents constituted 7.4% of total assets in 2024, down from 10.7% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 8.0% in 2019.
- Asset Diversification: The largest asset category is accounts receivable at 2.9% of total assets.
General Biologicals Corporation Competitors by Total Assets
Key competitors of General Biologicals Corporation based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
General Biologicals Corporation - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - General Biologicals Corporation generates 0.07x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - General Biologicals Corporation is currently not profitable relative to its asset base.
General Biologicals Corporation - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.32 | 1.02 | 5.62 |
| Quick Ratio | 1.11 | 0.76 | 4.43 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$106.69 Million | NT$ 9.09 Million | NT$ 452.94 Million |
General Biologicals Corporation - Advanced Valuation Insights
This section examines the relationship between General Biologicals Corporation's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.22 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 34.2% |
| Total Assets | NT$3.41 Billion |
| Market Capitalization | $4.59 Million USD |
Valuation Analysis
Below Book Valuation: The market values General Biologicals Corporation's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: General Biologicals Corporation's assets grew by 34.2% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for General Biologicals Corporation (2019–2024)
The table below shows the annual total assets of General Biologicals Corporation from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | NT$3.41 Billion | +34.22% |
| 2023-12-31 | NT$2.54 Billion | +63.64% |
| 2022-12-31 | NT$1.55 Billion | +22.63% |
| 2021-12-31 | NT$1.26 Billion | +51.74% |
| 2020-12-31 | NT$833.28 Million | +196.22% |
| 2019-12-31 | NT$281.30 Million | -- |